Jennison Associates LLC Takes $20.25 Million Position in Repligen Corporation $RGEN

Key Points

• Jennison Associates bought a new stake of 123,600 shares in Repligen worth about $20.25 million, representing roughly 0.22% of the company at quarter-end.
• Repligen beat quarterly estimates with $0.49 EPS (vs. $0.44 expected) and $197.9 million revenue (up 18.1% YoY), and gave FY2026 EPS guidance of 1.93–2.01 (analysts average 1.97).
• Analyst views are mixed but lean positive: MarketBeat shows an average rating of "Moderate Buy" with an average price target of $170.25, while individual targets range from $145 to $208.

Jennison Associates LLC bought a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 123,600 shares of the biotechnology company's stock, valued at approximately $20,253,000. Jennison Associates LLC owned approximately 0.22% of Repligen at the end of the most recent quarter.

Several other large investors have also modified their holdings of RGEN. Bayforest Capital Ltd acquired a new stake in Repligen during the 4th quarter worth $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen during the 4th quarter worth $33,000. Measured Wealth Private Client Group LLC acquired a new stake in Repligen during the 3rd quarter worth $29,000. Farther Finance Advisors LLC boosted its stake in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 128 shares during the period. Finally, CWM LLC boosted its stake in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 135 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Stock Down 0.9%

Shares of Repligen stock opened at $117.20 on Friday. The company has a market cap of $6.61 billion, a P/E ratio of 137.88, a PEG ratio of 2.28 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37. Repligen Corporation has a one year low of $109.50 and a one year high of $175.77. The firm has a fifty day moving average of $121.56 and a two-hundred day moving average of $144.70.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. Repligen's quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, analysts forecast that Repligen Corporation will post 1.97 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Canaccord Genuity Group decreased their price target on shares of Repligen from $165.00 to $145.00 and set a "hold" rating for the company in a research note on Monday, April 20th. Barclays decreased their price target on shares of Repligen from $175.00 to $145.00 and set an "overweight" rating for the company in a research note on Tuesday, April 14th. Weiss Ratings cut shares of Repligen from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Tuesday, March 3rd. HC Wainwright increased their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a "buy" rating in a research note on Monday, March 23rd. Finally, Roth Mkm assumed coverage on shares of Repligen in a research note on Friday, April 17th. They set a "buy" rating and a $160.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $170.25.

Repligen Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.